Literature DB >> 9735129

Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia.

D D Chi1, J F Moley.   

Abstract

Medullary thyroid cancer is a tumor of the thyroid C cells that occurs in sporadic and hereditary clinical settings. Genetic testing of at-risk individuals is available and has been applied to patient management. Plasma calcitonin levels are a sensitive marker for the presence of disease. Surgery offers the best hope for cure and also is an effective modality for managing metastatic and recurrent disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9735129

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

1.  Sporadic medullary thyroid carcinoma with a pedunculated intraluminal internal jugular vein recurrence: A case report and literature review.

Authors:  Darren K Patten; Rashpal Flora; Neil Tolley; Fausto Palazzo
Journal:  Int J Surg Case Rep       Date:  2011-11-22

2.  A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia.

Authors:  G I Uwaifo; A T Remaley; M Stene; J C Reynolds; P M Yen; R H Snider; K L Becker; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

Review 3.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  B Zarebczan; H Chen
Journal:  Minerva Chir       Date:  2010-02       Impact factor: 1.000

4.  Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).

Authors:  M Nocera; E Baudin; G Pellegriti; A F Cailleux; C Mechelany-Corone; M Schlumberger
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.